लोड हो रहा है...
P17.22 LOMUSTIN OR BEVACIZUMAB AT FIRST RECURRENCE OF GLIOBLASTOMA
Bevacizumab is registered in the U.S. for the treatment of recurrent glioblastoma based on improved PFS in uncontrolled phase II trials; Recently, a randomized controlled phase II trial studied lomustin, bevacizumab or the combination of both compounds in the treatment of glioblastoma at first recur...
में बचाया:
| मुख्य लेखकों: | , , , |
|---|---|
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
Oxford University Press
2014
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4185719/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou174.352 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|